


Long-Term Prophylactic Treatment With Oral Deucricbant Improves Disease Control and Health-Related Quality of Life in Participants With Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study

Markus Magerl^{1,2}, John Anderson³, Francesco Arcoletti⁴, Emel Ayygören-Pürsün⁵, Mauro Cancian⁶, Hugo Chapdelaine⁷, Niall Conlon⁸, Efreem Eren⁹, Mark Gompels¹⁰, Sofia Grigoriadou¹¹, Maria D. Guarino¹², Padmalal Gurugama¹³, Sorena Kiani-Alikhan¹⁴, Tamar Kinaciyan¹⁵, Michael E. Manning¹⁶, Marcin Stobiecki¹⁷, Michael D. Tarzi¹⁸, Anna Valeriva¹⁹, H. James Wedner²⁰, William H. Yang²¹, Andrea Zanichelli^{22,23}, Rafael Crabbé²⁴, Susan Mulders²⁵, Jonathan Levy²⁶, Ulrich Freudensprung²⁷, Umar Katbeh²⁷, Jochen Knolle²⁸, Anne Lesage²⁹, Peng Lu²⁶, Marc A. Riedl³⁰

¹Charité – Universitätsmedizin Berlin, Institute of Allergology, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany; ³AllerVie Health, Clinical Research Center of Alabama, Birmingham, AL, USA; ⁴AOR Villa Sofia-Cervello, UOC di Patologia Clinica e Immunologia, Palermo, Italy; ⁵University Hospital Frankfurt, Department for Children and Adolescents, Goethe University Frankfurt, Frankfurt, Germany; ⁶University Hospital of Padua, Department of Systems Medicine, Padua, Italy; ⁷Université de Montréal, CHU de Montréal, Montréal, QC, Canada; ⁸St. James's Hospital and Trinity College, Wellcome Trust CRF, Dublin, Ireland; ⁹University Hospital Southampton NHS Foundation Trust, Southampton, UK; ¹⁰North Bristol NHS Trust, Bristol, UK; ¹¹Barts Health NHS Trust, London, UK; ¹²Ospedale di Civitanova Marche, Civitanova Marche, Italy; ¹³Cambridge University Hospitals NHS Foundation Trust, Department of Clinical Immunology, Cambridge, UK; ¹⁴Royal Free London NHS Foundation Trust, London, UK; ¹⁵Medical University of Vienna, Department of Dermatology, Vienna, Austria; ¹⁶Allergy, Asthma and Immunology Associates, Ltd., Scottsdale, AZ, USA; ¹⁷Jagiellonian University Medical College, Department of Clinical and Environmental Allergology, Krakow, Poland; ¹⁸University Hospitals Sussex NHS Foundation Trust, Department of Respiratory Medicine, Brighton, UK; ¹⁹Medical University of Sofia, Department of Allergology, Sofia, Bulgaria; ²⁰Washington University School of Medicine, Division of Allergy and Immunology, Department of Medicine, St Louis, MO, USA; ²¹Ottawa Allergy Research Corporation, Department of Medicine, University of Ottawa, Ottawa, ON, Canada; ²²Università degli Studi di Milano, Dipartimento di Scienze Biomediche per la Salute, Milan, Italy; ²³R.C.C.S., Policlinico San Donato, Centro Angioedema, UO Medicina, Milan, Italy; ²⁴RC Consultancy, Bassins, Switzerland; ²⁵Mulders Clinical Consulting, Groesbeek, The Netherlands; ²⁶Pharvaris Inc., Lexington, MA, USA; ²⁷Pharvaris GmbH, Zug, Switzerland; ²⁸JCK Consult, Frankfurt, Germany; ²⁹GrayMatters Consulting, Schilde, Belgium; ³⁰University of California San Diego, Division of Allergy and Immunology, La Jolla, CA, USA

Key takeaways

The ongoing Phase 2 CHAPTER-1 open-label extension (OLE) provides additional evidence on the sustained effects of long-term prophylactic treatment with oral deucricbant on disease control, health-related quality of life (HRQoL), and treatment satisfaction for participants with hereditary angioedema (HAE).



AECT, Angioedema Control Test; AE-QoL, Angioedema Quality of Life Questionnaire; HRQoL, health-related quality of life; PGA-Change, Patient Global Assessment of Change; TSQM, Treatment Satisfaction Questionnaire for Medication.

Background

- Hereditary angioedema (HAE):** a bradykinin-mediated condition with painful swelling attacks affecting multiple locations in the body and negatively impacting HRQoL.¹⁻⁷
- Unmet need:** additional prophylactic treatments offering injectable-like efficacy, a well-tolerated profile, and ease of administration.⁸⁻¹¹
- Deucricbant:** a selective, bradykinin B2 receptor antagonist under development for both prophylactic and on-demand treatment of HAE attacks.¹¹⁻²²


Objective

To evaluate the impact of deucricbant treatment on disease control, HRQoL, and treatment satisfaction through 62 weeks in adult participants with HAE in the CHAPTER-1 OLE study (data snapshot 10 June 2024).¹⁸

Methods

- CHAPTER-1 (NCT05047185)*:** a two-part, Phase 2 study.¹⁸
 - Part 1 randomized controlled trial (RCT) is complete. Part 2 OLE is ongoing.
- Eligible participants:** adults diagnosed with HAE-1/2, not receiving other prophylactic treatments at screening, and with a pre-specified minimum number of attacks.

Figure 1. CHAPTER-1 study design



IR, immediate release; OLE, open-label extension; R, randomization; RCT, randomized controlled trial. ^aDeucricbant IR capsule, 10 mg twice daily. ^bDeucricbant IR capsule, 20 mg twice daily.


- Patient Global Assessment of Change (PGA-Change)²³:** a tool to measure the change in the impact of HAE on patients' HRQoL since starting study treatment compared with pre-treatment:



- Angioedema Quality of Life Questionnaire (AE-QoL)²⁴⁻²⁶:** a tool validated for HAE and comprising a 17-item questionnaire across four domains, "functioning", "fatigue/mood", "fear/shame", and "nutrition", on a five-point response scale:



- Angioedema Control Test (AECT)^{27,28}:** a four-item questionnaire with a five-point response scale developed and validated to retrospectively quantify disease control and aid management decisions in patients with recurrent angioedema (AECT-4Wk – four-week recall used):




- Treatment Satisfaction Questionnaire for Medication (TSQM) Version II²⁹:** an 11-item questionnaire to gauge patients' satisfaction with "effectiveness", "side effects", "convenience", and "global satisfaction" of a medication:



Results

- All 30 participants who completed the Part 1 RCT enrolled in the Part 2 OLE.
 - At data cutoff: 5 participants had discontinued. 25 were ongoing, of which 14 had reached at least the week 62 visit.
- This analysis included the 14 participants who had reached at least the week 62 visit.
 - Mean (SD) exposure to deucricbant 40 mg/day for these 14 participants in the OLE: 16.9 (3.0) months.
 - Min-max exposure in the OLE: 12.4–20.8 months. Maximum exposure to deucricbant in the entire study: 23.7 months.


Figure 2. PGA-Change: HRQoL improved at weeks 12 and 62 compared with study baseline



HRQoL, health-related quality of life; IR, immediate release; OLE, open-label extension; PGA-Change, Patient Global Assessment of Change; RCT, randomized controlled trial. n = number of participants with PGA-Change results at the given week. ^aDeucricbant IR capsule, 10 mg twice daily. ^bDeucricbant IR capsule, 20 mg twice daily.


Results

Figure 3. AE-QoL: Improvement in HRQoL by week 4 and effects sustained through week 62




AE-QoL, Angioedema Quality of Life Questionnaire; HRQoL, health-related quality of life; IR, immediate release; OLE, open-label extension; RCT, randomized controlled trial. n = number of participants with AE-QoL data at the given week. ^aDeucricbant IR capsule, 10 mg twice daily. ^bDeucricbant IR capsule, 20 mg twice daily.

Figure 4. AECT: Improvement in disease control by week 4 and effects sustained through week 62




AECT, Angioedema Control Test; IR, immediate release; OLE, open-label extension; RCT, randomized controlled trial. n = number of participants with AECT results at the given week. ^aDeucricbant IR capsule, 10 mg twice daily. ^bDeucricbant IR capsule, 20 mg twice daily.

Figure 5. AECT: 90% of participants at 12 weeks and 100% of participants at 62 weeks receiving deucricbant showed well-controlled HAE




AECT, Angioedema Control Test; HAE, hereditary angioedema; IR, immediate release; OLE, open-label extension; RCT, randomized controlled trial. n = number of participants randomized to each treatment group in the RCT. n = number of participants with AECT results at the given week. ^aDeucricbant IR capsule, 10 mg twice daily. ^bDeucricbant IR capsule, 20 mg twice daily.

Figure 6. TSQM: Greater patient satisfaction with effectiveness vs placebo at week 12 was sustained in the OLE



IR, immediate release; OLE, open-label extension; RCT, randomized controlled trial; TSQM, Treatment Satisfaction Questionnaire for Medication. n = number of participants with TSQM results at the given week. ^aDeucricbant IR capsule, 10 mg twice daily. ^bDeucricbant IR capsule, 20 mg twice daily.

Figure 7. TSQM: Greater overall patient satisfaction vs placebo at week 12 was sustained in the OLE



IR, immediate release; OLE, open-label extension; RCT, randomized controlled trial; TSQM, Treatment Satisfaction Questionnaire for Medication. n = number of participants with TSQM results at the given week. ^aDeucricbant IR capsule, 10 mg twice daily. ^bDeucricbant IR capsule, 20 mg twice daily.

This presentation includes data for an investigational product not yet approved by regulatory authorities.

References

- Busse PJ, et al. *N Engl J Med*. 2020;382:1136-48.
- Maurer M, et al. *Allergy*. 2022;77:1961-90.
- Bork K, et al. *Allergy Asthma Clin Immunol*. 2021;17:40-4.
- Bygum A, et al. *Front Med*. 2017;4:212.
- Mendivil J, et al. *Orphanet J Rare Dis*. 2021;16:94.
- Chong-Neto HJ. *World Allergy Organ J*. 2023;16:100758.
- Lumry WR, et al. *Allergy Asthma Proc*. 2010;31(5):407-14.
- Bouillet L, et al. *Allergy Asthma Proc*. 2022;43:406-12.
- Coveille B, et al. *Future Pharmacol*. 2024;4:41-53.
- Center for Biologics Evaluation and Research. The voice of the patient – hereditary angioedema. US Food and Drug Administration; May 2018. Accessed May 20, 2025. <https://www.fda.gov/media/113509/download>.
- Betschel SD, et al. *J Allergy Clin Immunol Pract*. 2023;11:2315-25.
- Lesage A, et al. *Int Immunopharmacol*. 2022;105:108523.
- RAPiDe-1. <https://clinicaltrials.gov/study/NCT04618211>. Accessed May 20, 2025.
- RAPiDe-2. <https://www.clinicaltrials.gov/study/NCT05396105>. Accessed May 20, 2025.
- RAPiDe-3. <https://clinicaltrials.gov/study/NCT06343779>. Accessed May 20, 2025.
- Maurer M, et al. Presented at: AAAAI; February 24–27, 2023; San Antonio, TX, USA.
- CHAPTER-1. <https://www.clinicaltrials.gov/study/NCT05047185>. Accessed May 20, 2025.
- Ayygören-Pürsün E, et al. Presented at: EAAAC; May 31–June 3, 2024; Valencia, Spain.
- CHAPTER-3. <https://clinicaltrials.gov/study/NCT06669754>. Accessed May 20, 2025.
- CHAPTER-4. <https://clinicaltrials.gov/study/NCT06798981>. Accessed May 20, 2025.
- Green K, et al. Presented at: ACAAI 2022; November 10–14, 2022; Louisville, KY, USA.
- Guy W (ed). *ECDEU Assessment Manual for Psychopharmacology*. 1974. 24. Weller K, et al. *Allergy*. 2012;67:1289-98.
- Weller K, et al. *Allergy*. 2016;71:1203-9.
- Vanya M, et al. *J Patient Rep Outcomes*. 2023;7:33.
- Weller K, et al. *Allergy*. 2020;75:1165-77.
- Weller K, et al. *J Allergy Clin Immunol Pract*. 2020;8:2050-7.
- Atkinson MJ, et al. *Value Health*. 2005;8(1):S9–24.